Loading…
Indrayani Biotech (BSE 526445)₹7.78−0.89%Other Agricultural Products
In the Jun 2026 quarter (consolidated), Indrayani Biotech reported sales of ₹37.55 Cr, up 29.5% from Jun 2025, and net profit of ₹0.55 Cr, up 223.5% year on year. For the year to Mar 2026, sales were ₹137 Cr and net profit ₹2.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 40.26 | 38.95 | 44.24 | 31.39 | 30.72 | 17.26 | 50.39 | 29.00 | 35.84 | 34.89 | 37.59 | 37.55 |
| Expenses | 33.22 | 35.68 | 34.26 | 25.59 | 25.74 | 14.43 | 56.37 | 26.97 | 33.55 | 32.30 | 35.57 | 36.31 |
| Operating Profit | 7.30 | 3.46 | 10.19 | 5.99 | 5.12 | 2.93 | −5.75 | 2.19 | 2.46 | 2.80 | 2.23 | 1.47 |
| OPM % | 18.1% | 8.9% | 23.0% | 19.0% | 16.7% | 16.9% | −11.3% | 7.5% | 6.8% | 8.0% | 5.9% | 3.9% |
| Other Income | 0.08 | 0.07 | 1.02 | 0.03 | 0.29 | 0.00 | 2.77 | 1.05 | 1.79 | 0.82 | 0.87 | 1.58 |
| Interest | 0.94 | 1.42 | 5.53 | 0.84 | 1.43 | 1.04 | 7.10 | 2.18 | 1.90 | 2.48 | 3.09 | 1.38 |
| Depreciation | 0.92 | 1.04 | 0.95 | 4.24 | 2.78 | 1.47 | −1.71 | 0.85 | 1.29 | 1.00 | 1.14 | 1.11 |
| Profit before tax | 5.53 | 1.08 | 4.72 | 0.93 | 1.19 | 0.42 | −8.30 | 0.20 | 1.05 | 0.13 | −1.10 | 0.57 |
| Tax % | 0.0% | 0.0% | 0.0% | 9.6% | −1.7% | 18.6% | 2.5% | 23.8% | 14.1% | 21.4% | −187.4% | 8.6% |
| Net Profit | 5.56 | 1.09 | 4.75 | 0.86 | 1.23 | 0.36 | −8.55 | 0.17 | 0.92 | 0.13 | 0.99 | 0.55 |
| EPS (Rs) | 0.93 | 0.12 | 0.49 | 0.10 | 0.15 | 0.02 | −1.08 | 0.01 | 0.04 | 0.01 | 0.12 | 0.06 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 49.84 | 20.91 | 60.75 | 162 | 164 | 130 | 137 | 146 |
| Expenses | 47.11 | 26.03 | 54.09 | 145 | 142 | 124 | 128 | 138 |
| Operating Profit | 3.01 | −5.01 | 7.02 | 17.05 | 24.04 | 6.01 | 10.02 | 8.96 |
| OPM % | 6.0% | −24.0% | 11.0% | 11.1% | 14.1% | 4.9% | 7.0% | 6.1% |
| Other Income | 0.00 | −3.99 | 0.00 | 3.98 | 0.99 | 2.99 | 4.98 | 5.06 |
| Interest | 1.01 | 2.01 | 2.01 | 6.02 | 10.03 | 12.05 | 10.03 | 8.85 |
| Depreciation | 1.01 | 0.00 | 1.01 | 3.01 | 3.99 | 2.99 | 4.01 | 4.54 |
| Profit before tax | 0.99 | −10.98 | 3.99 | 11.97 | 10.99 | −5.99 | 0.00 | 0.65 |
| Tax % | 0.0% | 0.0% | 0.0% | 3.0% | 5.0% | 6.0% | −620.0% | — |
| Exceptional items | 0.00 | −3.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 1.01 | −11.04 | 4.01 | 12.03 | 10.04 | −6.02 | 2.01 | 2.59 |
| EPS (Rs) | 1.30 | −1.90 | 0.75 | 1.48 | 0.80 | −0.77 | 0.27 | 0.23 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3.99 | 33.97 | 33.97 | 33.94 | 45.88 | 45.90 | 45.90 |
| Reserves | 27.03 | −15.03 | −10.04 | 12.01 | 22.01 | 27.01 | 27.01 |
| Borrowings | 14.02 | 16.06 | 19.08 | 79.16 | 113 | 137 | 128 |
| Other Liabilities | 6.96 | 5.02 | 7.99 | 30.85 | 53.74 | 57.72 | 51.75 |
| Total Liabilities | 51.00 | 40.02 | 51.00 | 156 | 234 | 268 | 253 |
| Fixed Assets | 17.07 | 15.06 | 17.07 | 57.21 | 62.21 | 58.18 | 60.19 |
| CWIP | 13.99 | 13.99 | 12.99 | 13.99 | 19.98 | 26.01 | 26.97 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 20.94 | 10.97 | 21.94 | 84.76 | 151 | 183 | 166 |
| Inventories | 4.99 | 1.01 | 2.01 | 11.99 | 42.03 | 40.99 | 37.99 |
| Trade receivables | 6.98 | 4.99 | 13.94 | 29.90 | 39.84 | 58.82 | 58.78 |
| Cash & equivalents | 0.99 | 0.99 | 1.99 | 2.99 | 0.99 | 0.00 | 3.99 |
| Total Assets | 51.00 | 40.02 | 51.00 | 156 | 234 | 268 | 253 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 5.99 | 0.00 | 3.99 | 15.99 | −29.96 | −6.99 | 31.96 |
| Cash from investing activity | −3.99 | −0.99 | −0.99 | −46.95 | −15.97 | 24.96 | −12.97 |
| Cash from financing activity | −1.01 | 0.00 | −3.01 | 32.97 | 43.96 | −18.01 | −14.99 |
| Net cash flow | 0.99 | −0.99 | 0.99 | 1.99 | −1.99 | 0.00 | 3.99 |
| Capex | 3.48 | 0.69 | 1.20 | 40.94 | 16.44 | 1.37 | 8.28 |
| Free cash flow | 1.99 | 0.00 | 2.99 | −24.97 | −46.93 | −7.99 | 22.98 |
| CFO / OP % | 215.0% | −5.0% | 61.1% | 94.1% | −128.0% | −123.9% | 328.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 51 | 83 | 83 | 66 | 86 | 164 | 154 |
| Inventory days | 57 | 25 | 14 | 44 | 159 | 182 | 147 |
| Days payable | 71 | 78 | 53 | 82 | 142 | 105 | 56 |
| Cash conversion cycle | 37 | 31 | 45 | 29 | 105 | 242 | 246 |
| Working capital days | 29 | −60 | −13 | 5 | 126 | 210 | 162 |
| ROCE % | — | −13.0% | 16.0% | 23.0% | 14.0% | 3.0% | 4.0% |
For the Jun 2026 quarter, Indrayani Biotech reported sales of ₹37.55 Cr, up 29.5% year on year and net profit of ₹0.55 Cr, up 223.5% year on year. The operating margin was 3.9%.
Indrayani Biotech's sales for the year to Mar 2026 were ₹137 Cr; over the last twelve months they were ₹146 Cr.
Net profit for the year to Mar 2026 was ₹2.01 Cr, and ₹2.59 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.23.
Indrayani Biotech reported borrowings of ₹128 Cr at Mar 2026, against cash and equivalents of ₹3.99 Cr.
Cash from operations was ₹31.96 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹22.98 Cr.